April 13, 2009 Centocor Ortho Biotech Inc. and Schering-Plough Corporation today announced that Health Canada has granted approval of SIMPONI (golimumab) as a once-monthly, subcutaneous therapy for the treatment of moderately to severely active rheumatoid arthritis, active psoriatic arthritis and active ankylosing spondylitis.
The details can be read here.
No comments:
Post a Comment